Physiological Basis of Cardiovascular Protection by SGLT2 Inhibitors in Diabetic Ischemic Heart Disease

Authors

  • Nadine Ahmed Raafat, Reham Hassan El-Azoney, Sara Tarek Mohammed El-Esawey, Sara G. Seada Author

DOI:

https://doi.org/10.48047/60np5h83

Keywords:

Cardiovascular Protection, SGLT2 Inhibitors, Diabetic Ischemic Heart Disease

Abstract

Background: Diabetes mellitus is a major global health problem and represents a leading contributor to cardiovascular morbidity and 
mortality. Among the various cardiovascular complications associated with diabetes, ischemic heart disease remains the most prevalent and life-threatening condition. Chronic hyperglycemia

Downloads

Download data is not yet available.

References

Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus. Circulation. 2016;133(24):2459–2502. doi:10.1161/CIRCULATIONAHA.116.022194

Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624–638. doi:10.1161/CIRCRESAHA.117.311586

Downloads

Published

2024-11-20

Issue

Vol. 53 No. 03 (2024): Year 2024, Volume 53, Issue 3

Section

Original

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  1. Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  2. Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  3. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices:

You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .

No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.

How to Cite

Physiological Basis of Cardiovascular Protection by SGLT2 Inhibitors in Diabetic Ischemic Heart Disease (Nadine Ahmed Raafat, Reham Hassan El-Azoney, Sara Tarek Mohammed El-Esawey, Sara G. Seada , Trans.). (2024). Cuestiones De Fisioterapia, 53(03), 7105-7113. https://doi.org/10.48047/60np5h83